Related Experiment Video
Updated: Jul 10, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
CYP2F1 genetic polymorphism: identification of interethnic variations
G Tournel1, C Cauffiez, J Leclerc
1Equipe d'accueil 2679, Faculté de Médecine de Lille, Lille, France. gilles.tournal@univ-lille2.fr
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|October 19, 2007
Summary
Genetic variations in human cytochrome P450 2F1 (CYP2F1) impact lung cancer risk. This study found significant ethnic differences in the frequency of a specific CYP2F1 frameshift mutation, c.14_15insC.
Area of Science:
- Pharmacogenomics
- Molecular epidemiology
- Cancer genetics
Background:
- Human cytochrome P450 2F1 (CYP2F1) is primarily expressed in lung tissue.
- CYP2F1 metabolizes pneumotoxicants, influencing susceptibility to lung cancer.
- Genetic variations in CYP2F1 may explain interindividual and interethnic differences in lung tumorigenesis.
Purpose of the Study:
- To compare the frequency of the CYP2F1 frameshift mutation c.14_15insC across diverse ethnic populations.
- To investigate potential ethnic variations in CYP2F1 gene polymorphisms.
- To provide data for future studies on CYP2F1 and lung cancer risk.
Main Methods:
- Genotyping analysis of the CYP2F1 gene.
- Population-based study design.
- Comparison of mutation frequencies across French, Gabonese, Senegalese, and Tunisian samples.
Main Results:
- The frequency of the c.14_15insC polymorphism varied significantly among ethnic groups.
- Observed frequencies were 26.1% (French), 51.6% (Gabonese), 42.7% (Senegalese), and 22.9% (Tunisian).
- These results highlight substantial interethnic variation in the CYP2F1 gene.
Conclusions:
- Significant ethnic variations exist in the frequency of the CYP2F1 c.14_15insC mutation.
- These findings support further research into CYP2F1 haplotypes and their association with lung cancer incidence across different ethnicities.
- Understanding these genetic disparities is crucial for personalized lung cancer risk assessment.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...